COVID-19 Update: Information and resources can be found here.

The Glucose Transporter Type I Deficiency Syndrome Research Consortium (G1DRC)

What is the G1DRC?

The G1DRC, based at UT Southwestern Medical Center, includes an international array of nonprofit medical research and patient care institutions in partnership with patient advocacy organizations with the sole mission of working together to improve the availability of G1D information and resources, treatment, clinical studies, and general awareness for both patients and the medical community. Juan M. Pascual, M.D., Ph.D., is the Principal Investigator of the G1DRC. G1DRC operates in a full nonprofit manner and follows high ethical standards.

Who is a member of G1DRC or can join G1DRC?

  • Investigators, physicians, and nonprofit organizations with a record of G1D excellence or a potential to significantly contribute to G1D.
  • No commercial interests or relations relevant to G1D are a part of G1DRC. To that effect, G1DRC members sign an initial and, later, annual disclosure of potential financial or commercial interests relevant to G1D.

What are the immediate goals of the G1DRC?

  • Provide the best possible care to patients affected by G1D by generating standards of care.
  • Improve collaborations for the study of G1D.
  • Achieve deeper understanding of G1D, its mechanisms and manifestations.
  • Find new treatments.
  • Create and expand treatment studies in patients.
  • Educate society about the avenues for the approval of medical foods, drugs, devices, and other interventions, and the pros and cons of each approach.
  • Put patients’ needs first by broadly advocating for safe and affordable treatments such as medical foods, drugs, and devices, or other interventions to be widely available in the most ethical manner.

G1DRC Resources

:: G1D Registry
:: G1D information from the National Institutes of Health
:: G1D Information from The Child Brain Foundation
:: GeneReview for G1D
:: G1D conferences